Etelcalcetide Trial in Children with Kidney Disease
Phase 3
56
about 9.8 years
0–18
10 sites in CA, CO, MO +6
About this study
Researchers are testing a treatment called Etelcalcetide in children with kidney disease and high parathyroid hormone levels. This treatment aims to help manage these conditions, which can cause bone problems and other complications. The trial will last for about 3 years.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Etelcalcetide
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
etelcalcetide
injection (Injection)
Primary: Percentage Change from Baseline in Mean iPTH During the EAP
Secondary: Change from Baseline in Diastolic Blood Pressure, Change from Baseline in Heart Rate, Change from Baseline in Systolic Blood Pressure, Change in Weight, Maximum Serum Concentration (Cmax) of Etelcalcetide, Mean Change from Baseline in Predialysis iPTH from Baseline during the EAP, Number of Participants who Experienced Adverse Events (AEs), Percentage Change from Baseline in Corrected Total Serum Ca from Baseline During the EAP
Renal